Scientific Programme

2023 Programme

Highlights

Through didactic lectures, tandem talks, debates, keynote lectures, and selected abstract presentations, the Scientific Programme examines a range of gastrointestinal malignancies and offers a mix of dynamic education and exchange.

  • Cancer of the Pancreas
    • Hereditary Predisposition to Pancreatic Cancer & Surveillance of Patients with Hereditary Predisposition
    • Diagnosis and Management of Premalignant Pancreatic Lesions - IPMN
    • Debate:Molecular Therapies in Pancreatic Ductal Adenocarcinoma: NGS for All or None
    • Flash: Laparoscopic vs Robotic Surgery
    • Flash: What is Resectable Pancreatic Cancer & Is There A Role for Complex Surgery – Arterial Resection
    • Debate: Resectable Pancreatic Cancer: Neoadjuvant Chemotherapy in All Patients?
    • Current Standards & New Emerging Options in Metastatic Pancreatic Cancer
       
  • Cancer of the Biliary Tract
    • Molecular Unraveling of Biliary Tract Cancer
    • Debate: Are We Ready for Targeted Agents in First-Line Treatment of Advanced Biliary Tract Cancer?
    • Locally Advanced Bile Duct Cancer: Criteria and Approaches in Borderline Resectable Disease
       
  • ESMO Session: Focus on Young Oncologists (YO) in Collaboration With ESMO Young Oncologist Committee (YOC)
     
  • Meet the Experts
     
  • Esophageal and Gastric Cancers
    • Endoscopic Management of Early Esophageal and Gastric Cancer
    • Strategy in Oligometastatic Upper GI Cancer
    • Are we ready to Integrate Immunotherapy in Adjuvant and/or Neoadjuvant Settings in Upper GI Cancer?
    • Keynote Lecture: Molecular Classification of Gastric Cancer
    • Flash: Key Facts on PDL Testing
    • Flash: Locally Advanced MSI-H Upper GI Cancer: What is the Optimal Approach?
    • Checkpoint Inhibition in Squamous Cell Cancer of the Esophagus
    • Checkpoint Inhibition in Metastatic Gastric Adenocarcinoma
    • New Targets and Agents in Upper GI Cancer
       
  • Hepatocellular Carcinoma
    • Pathogenesis and Subtypes of HCC: NASH & Viral Etiology
    • Diagnostic and Imaging Challenges in HCC
    • Are we ready to Integrate Systemic Treatment in Early Stages of HCC
    • How to Integrate and Sequence New Agents in Advanced HCC?
    • Cases With Panel Discussion: Management Strategy in HCC: Locoregional Treatment vs Systemic Treatment
    • How to Integrate and Sequence New Agents in HCC
       
  • Minisymposium: The Role of Functional Imaging in GI Cancer
     
  • Minisymposium: Special Topics in Young Adults with Cancer
     
  • Molecular Marker Platforms: Focus on Liquid Biopsies
     
  • Emerging Targets in GI Cancer
    • Targeting RAS Mutations
    • Targeting the HER2 Pathway in GI Cancer
    • Targeting Claudin 18.2 in GI Cancer
       
  • Rectal Cancer
    • MRI: New Data and Learnings in Rectal Cancer
    • Debate: Is TNT standard of Care in Rectal Cancer?
       
  • Flashes
    • Surveillance in Non-Operative Management/Watch & Wait Strategy: How to do?
    • How to Integrate CPI in MSI-H Rectal Cancer: Double CPI? Duration? Role of RT?
    • Is Robotic Surgery Taking off in Rectal Cancer
    • The Challenge of Lateral Lymph Nodes
       
  • Cases With Panel Discussion: Oligometastatic Rectal Cancer
     
  • Adjuvant and Neoadjuvant Treatment of Colon Cancer
     
  • Immune Mechanisms and Microbiome in GI Tumors
    • Resistance Factors to IOs
    • Microbiome and Colorectal Cancer
       
  • Predicting and Managing Rare Toxicities in GI Cancer Patients
    • Toxicity Management: Pneumonitis and Interstitial Lung Disease (ILD)
    • Toxicity Management: Nausea and Vomiting
       
  • Surgical Advances in GI Oncology
     
  • Colorectal Cancer: Metastatic Disease
    • Algorithms in First-Line and Second-Line Metastatic Disease
       
  • GI Oncology: The Past, Present, and Future